Cytosorbents (CTSO) Net Income towards Common Stockholders (2010 - 2026)
Cytosorbents (CTSO) posted Net Income towards Common Stockholders of -$5.1 million for Q1 2026, up 6.69% on a QoQ basis from -$5.5 million in Q4 2025, and down 246.79% year-over-year from $3.5 million in Q1 2025.
Cytosorbents (CTSO) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Cytosorbents' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 246.79% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (up 26.44% YoY) and the FY2025 annual result came in at -$8.2 million, up 60.43% from the prior year.
- Net Income towards Common Stockholders was -$5.1 million for Q1 2026 at Cytosorbents, up from -$5.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.9 million in Q2 2025 and bottomed at -$12.2 million in Q3 2022.
- A 5-year average of -$5.6 million and a median of -$5.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 661.61% — and 2025, when it jumped 145.34%.
- Cytosorbents' Net Income towards Common Stockholders stood at -$766128.0 in 2022, then tumbled by 661.61% to -$5.8 million in 2023, then declined by 29.69% to -$7.6 million in 2024, then grew by 27.36% to -$5.5 million in 2025, then grew by 6.69% to -$5.1 million in 2026.
- Business Quant data shows CTSO's Net Income towards Common Stockholders at -$5.1 million in Q1 2026, -$5.5 million in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.01 Bn | 175.72 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.76 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.90 Bn | 99.68 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 47.96 Bn | 44.29 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.44 Bn | 22.31 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Cytosorbents | 22.60 Mn | 17.80 Mn | 6.13 Mn | -5.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.13 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | -7.57 Mn |
| Sep 30, 2024 | -2.77 Mn |
| Jun 30, 2024 | -4.29 Mn |
| Mar 31, 2024 | -6.36 Mn |
| Dec 31, 2023 | -5.83 Mn |
| Sep 30, 2023 | -9.19 Mn |
| Jun 30, 2023 | -6.15 Mn |
| Mar 31, 2023 | -7.33 Mn |
| Dec 31, 2022 | -766,128.00 |
| Sep 30, 2022 | -12.20 Mn |
| Jun 30, 2022 | -10.88 Mn |
| Mar 31, 2022 | -8.97 Mn |
| Dec 31, 2021 | -9.31 Mn |
| Sep 30, 2021 | -6.41 Mn |
| Jun 30, 2021 | -4.68 Mn |